Year-end: the five things that earned a Tier-A grade in 2025

Verdict № 01

Tier A

Tranexamic acid (oral)

Holds Up

The most consequential pigmentation-supplement story of 2025. Three new RCTs confirmed the meta-analysis signal: 250 mg twice daily for 8–12 weeks produces measurable, replicated reduction in melasma severity, with adjunct topicals stacking favourably. Screen for VTE risk, work with a dermatologist, and treat as a course rather than a habit. Earned its Tier-A grade and held it through the year.

Bottom line

The supplement that genuinely changed our prescribing in 2025.

Verdict № 02

Tier A

Heliocare (Polypodium leucotomos)

Holds Up

Re-graded up from Tier B at the start of the year. The accumulated evidence on UV-induced erythema, MED extension, and PLE prophylaxis is now substantial enough that we recommend it routinely as an adjunct for melasma and photodermatosis patients. It does not replace SPF; it complements one. The peri-laser protocol literature, in particular, became hard to argue with.

Bottom line

Adjunct, not replacement. The clearest 2025 upgrade in our supplement section.

Verdict № 03

Tier A

Centella asiatica triterpenes (TECA)

Holds Up

The standardised triterpene fraction (asiaticoside, madecassoside, asiatic acid) — distinct from generic 'centella' marketing — earned the upgrade after a strong 2025 wound-healing literature year. The peri-procedure data is now unambiguous; the rosacea and barrier-flare data is encouraging if more modest. The labelling issue remains: not every centella product contains the standardised fraction.

Bottom line

Buy on standardised triterpene content. Marketing 'centella' is not the same molecule.

Tranexamic acid (oral)

Heliocare (Polypodium leucotomos)

Centella asiatica triterpenes (TECA)

Once a fortnight. Never a sell.